Lexicon Pharmaceuticals Inc
LXRXHealthcare|Biotechnology|USA
$2.23
-0.03 (-1.33%)
Tangible Book
$0.37
Clinical Trials (68)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06217302 Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Diabetic Nephropathies, Kidney Failure, Chronic | P3 | Recruiting | 150 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT06481891 A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy | P3 | Recruiting | 500 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT06435156 Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes | Type 1 Diabetes, Heart Failure | P2 | Recruiting | 320 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT05696366 Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes | Type 1 Diabetes | P1P2 | Active | 24 | RCT, Double-blind | Sotagliflozin, Volagidemab |
| NCT06933056 Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs | Platelet Function and Reactivity Tests | Early P1 | Recruiting | 20 | Open-label | Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order, Eliquis followed by 3 drugs in a random order |
| NCT03351478 Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin | Type 2 Diabetes Mellitus | P3 | Completed | 770 | RCT, Double-blind | Sotagliflozin, Empagliflozin, Placebo, Placebo |
| NCT02531035 A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone | Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood | P3 | Completed | 1,405 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT03242018 A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control | Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4 | P3 | Completed | 277 | RCT, Double-blind | Placebo, Sotagliflozin |
| NCT02026063 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms | Carcinoid Syndrome | P3 | Completed | 124 | Open-label | Telotristat etiprate |
| NCT01677910 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) | Carcinoid Syndrome | P3 | Completed | 135 | RCT, Double-blind | Telotristat etiprate, Placebo-matching telotristat etiprate |
| NCT02926937 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy | Type 2 Diabetes Mellitus | P3 | Completed | 399 | RCT, Double-blind | Sotagliflozin (SAR439954), Placebo |
| NCT07211802 CKM For Safe Use of SGLT2i in Type 1 Diabetes | Type 1 Diabetes (T1D) | P3 | Not Yet Recruiting | 52 | RCT, Double-blind | Sotagliflozin Low Dose, Sotagliflozin High Dose |
| NCT02063659 Telotristat Etiprate for Carcinoid Syndrome Therapy | Carcinoid Syndrome | P3 | Completed | 76 | RCT, Double-blind | Telotristat etiprate, Placebo |
| NCT03521934 Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) | Heart Failure, Type 2 Diabetes Mellitus | P3 | Terminated | 1,222 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT02384941 Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy | Type 1 Diabetes Mellitus | P3 | Completed | 793 | RCT, Double-blind | Placebo, Sotagliflozin |
| NCT02421510 Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy | Type 1 Diabetes Mellitus | P3 | Completed | 782 | RCT, Double-blind | Sotagliflozin, Sotagliflozin, Placebo |
| NCT03285594 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents | Type 2 Diabetes Mellitus | P3 | Completed | 571 | RCT, Double-blind | Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs) |
| NCT02926950 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin | Type 2 Diabetes Mellitus | P3 | Completed | 518 | RCT, Double-blind | Sotagliflozin (SAR439954), Placebo, Metformin |
| NCT03332771 Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy | Type 2 Diabetes Mellitus | P3 | Completed | 954 | RCT, Double-blind | Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo, Placebo |
| NCT03066830 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin | Type 2 Diabetes Mellitus | P3 | Completed | 507 | RCT, Double-blind | Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea |
| NCT03315143 Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk | Heart Failure, Type 2 Diabetes Mellitus | P3 | Terminated | 10,584 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT03242252 Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control | Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3 | P3 | Completed | 787 | RCT, Double-blind | Placebo, Sotagliflozin |
| NCT03386344 Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | Type 2 Diabetes Mellitus | P3 | Terminated | 376 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT02459899 Dose-ranging Study in Patients With Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P2 | Completed | 141 | RCT, Double-blind | Placebo, Sotagliflozin |
| NCT02383940 Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C | Type 1 Diabetes Mellitus | P2 | Completed | 87 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT00813098 Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome | Irritable Bowel Syndrome | P2 | Completed | 155 | RCT, Double-blind | LX1031 High Dose, LX1031 Low Dose, Placebo |
| NCT01528111 Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension | Primary Open-angle Glaucoma, Ocular Hypertension | P1P2 | Completed | 63 | RCT, Double-blind | LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle |
| NCT01742208 Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P2 | Completed | 36 | RCT, Double-blind | Sotagliflozin, Placebo, Sotagliflozin |
| NCT01456052 A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis | Ulcerative Colitis | P2 | Completed | 59 | RCT, Double-blind | Telotristat Etiprate, Placebo |
| NCT03910387 Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | P2 | Completed | 23 | RCT, Open-label | Gemcitabine, Nab-paclitaxel, Telotristat Ethyl |
| NCT00962065 Study of LX4211 in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P2 | Completed | 36 | RCT, Double-blind | LX4211 Low Dose, LX4211 High Dose, Placebo |
| NCT01104415 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome | Carcinoid Syndrome | P2 | Completed | 15 | RCT, Open-label | Telotristat etiprate |
| NCT06203002 A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) | Diabetic Peripheral Neuropathic Pain | P2 | Completed | 496 | RCT, Double-blind | Placebo (blinded), LX9211 (blinded) |
| NCT01494233 A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome | Irritable Bowel Syndrome | P2 | Completed | 373 | RCT, Double-blind | 250 mg LX1033 tablets, Placebo tablet |
| NCT00853047 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy | Carcinoid Syndrome | P2 | Completed | 23 | RCT, Double-blind | Telotristat etiprate, Octreotide LAR Depot, Placebo |
| NCT00691808 Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment | Age-Related Memory Disorders | P2 | Completed | 103 | RCT, Double-blind | LX6171 High Dose, LX6171 Low Dose, Placebo |
| NCT01376557 Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin | Type 2 Diabetes Mellitus | P2 | Completed | 299 | RCT, Double-blind | 75 mg LX4211, 200 mg LX4211, 400 mg LX4211, 200 mg LX4211, Placebo |
| NCT03292653 Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure | Cardiac Failure Aggravated | P2 | Terminated | 32 | RCT, Double-blind | Sotagliflozin, Placebo |
| NCT04662281 Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia | Postherpetic Neuralgia | P2 | Completed | 79 | RCT, Double-blind | Placebo, LX9211 |
| NCT00903383 Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate | Rheumatoid Arthritis | P2 | Completed | 208 | RCT, Double-blind | LX3305 low dose, LX3305 mid dose, LX3305 high dose, Placebo |
| NCT04455633 Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy, Diabetes | P2 | Completed | 319 | RCT, Double-blind | LX9211, LX9211 Matching Placebo |
| NCT03423446 Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment | Hepatic Impairment | P1 | Completed | 16 | Open-label | Telotristat Ethyl |
| NCT02647918 Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function | Renal Impairment, Healthy | P1 | Completed | 50 | Open-label | Sotagliflozin, Sotagliflozin |
| NCT01411800 An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects | Irritable Bowel Syndrome | P1 | Completed | 28 | RCT, Open-label | 250 mg capsule, 250 mg tablets |
| NCT02155205 A Thorough QT Study of Telotristat Etiprate | QT Interval | P1 | Completed | 48 | RCT, Double-blind | Telotristat etiprate, Placebo, Moxifloxacin |
| NCT02300350 DDI Study With Multiple-dose LX4211 and Single Dose Digoxin | Healthy | P1 | Completed | 24 | Open-label | Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly |
| NCT02195635 Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects | Drug Interactions | P1 | Completed | 24 | Open-label | Telotristat etiprate, Octreotide acetate |
| NCT02300363 DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin | Healthy | P1 | Completed | 24 | Open-label | Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly) |
| NCT01334242 A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects | Healthy | P1 | Completed | 14 | RCT, Double-blind | Schedule A, Schedule B, Schedule C, Schedule D, Schedule E |
| NCT01441232 A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics | Type 2 Diabetes Mellitus | P1 | Completed | 18 | RCT, Open-label | LX4211, Januvia® |
| NCT02373046 Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets | Healthy | P1 | Completed | 30 | RCT, Open-label | LX4211, LX4211 |
| NCT02157558 An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects | Drug Interactions | P1 | Completed | 24 | Open-label | Fexofenadine, Telotristat etiprate |
| NCT02471274 PK Study of Sotagliflozin in Subjects With Hepatic Impairment | Hepatic Impairment, Healthy | P1 | Completed | 32 | Open-label | sotagliflozin |
| NCT01292993 A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects | Type 2 Diabetes Mellitus | P1 | Completed | 18 | RCT, Open-label | 400 mg LX4211, 1000 mg metformin |
| NCT02157584 An Open-Label Food Effect Study of Telotristat Etiprate | Healthy | P1 | Completed | 22 | RCT, Open-label | Telotristat etiprate, Telotristat etiprate |
| NCT01916863 Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects | Healthy Subjects | P1 | Completed | 25 | RCT, Double-blind | LX4211 400 mg, canagliflozin 300 mg, LX4211 Placebo |
| NCT02147808 A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects | Drug Interactions | P1 | Completed | 24 | Open-label | Telotristat etiprate, Midazolam |
| NCT03302845 A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects | Drug-drug Interaction | P1 | Completed | 32 | RCT, Open-label | Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg |
| NCT01818232 Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects | Healthy | P1 | Completed | 8 | Open-label | [14C]-LX4211 |
| NCT02494609 Oral Contraceptive DDI Study | Healthy | P1 | Unknown | 30 | Open-label | sotagliflozin, oral contraceptive, oral contraceptive + sotagliflozin |
| NCT01916850 Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects | Healthy | P1 | Completed | 25 | RCT, Double-blind | LX4211 400 mg, LX4211 800 mg, LX4211 Placebo |
| NCT01417052 A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 10 | RCT, Double-blind | 50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo |
| NCT01913002 Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects | Healthy | P1 | Completed | 63 | RCT, Double-blind | LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo |
| NCT01555008 Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment | Type 2 Diabetes Mellitus, Renal Impairment | P1 | Completed | 31 | RCT, Double-blind | LX4211, LX4211 Placebo |
| NCT01188863 Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P1 | Completed | 15 | RCT, Open-label | 300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid) |
| NCT00847886 Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 15 | RCT, Double-blind | LX3305, LX3305 Placebo, Methotrexate |
| NCT01932528 An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males | Carcinoid Syndrome | P1 | Completed | 8 | Open-label | 500 mg [14C]-LX1606 |
| NCT04034745 Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain | Pancreatic Cancer, Neuroendocrine Tumors | Withdrawn | — | — | telotristat ethyl |